NCT04286841招募中不适用
The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- MPR
研究概览
简要总结
Several published clinical trials have shown the superiority of immunotherapy in neoadjuvant setting. Here we conducted this real world study to see whether neoadjuvant immunotherapy would bring MPR and survival benefits in NSCLC, for example, single agent immunotherapy or immunotherapy combination with chemotherapy. Furthermore biomarker analysis would be also performed to achieve personalized neoadjuvant immunotherapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent provided
- •Males or females aged ≥18 years
- •Able to comply with the required protocol and follow-up procedures、
- •Pathologically diagnosed of potentially resectable non-small cell lung cancer with stage II-IIIA (TNM 8th edition)
- •Measurable disease must be characterized according to RECIST 1.1 criteria
- •ECOG performance status 0-1
- •Regardless of PD-L1 expression
- •EGFR mutation (-) and ALK translocation (-)
- •Pulmonary function could be well tolerated by lobectomy or pneumonectomy
排除标准
- •EGFR mutation (+) or ALK translocation (+)
- •Active Central nervous system (CNS) metastases
- •Patients with active, known or suspected autoimmune disease.
- •Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement or unexpected conditions of recurrence in the absence of an external trigger are allowed to be included
- •Patients with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment
- •Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
- •Patients with a history of interstitial lung disease cannot be included if they have symptomatic ILD (Grade 3-4) and/or poor lung function. Patients with other active malignancy requiring concurrent intervention and/ or concurrent treatment with other investigational drugs or anti-cancer therapy
- •Patients with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/ dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period
- •Any medical, mental or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information
- •Patients who have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways Patients with positive test for hepatitis B virus surface antigen (HBVsAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating active hepatitis
- •Patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) Patients with history of allergy to study drug components excipients
- •Women who are pregnant or in the period of breastfeeding
- •Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study
- •In case of doubt please contact trial team.
研究组 & 干预措施
Neoadjuvant immunotherapy
干预措施: Immunotherapy (Drug)
结局指标
主要结局
MPR
时间窗: From the date of surgery up to 10 weeks
To evaluate the major pathological response (MPR) rate of participants
次要结局
- Objective Response Rate(From the date of surgery up to 10 weeks)
- MPR based on diverse PD-L1 expression(From the date of surgery up to 10 weeks)
- Percentage of Participants with Adverse Events(From the date of the first cycle of neoadjuvant treatment until 90 days after end of treatment, assessed up to 100 months)
- Progression Free Survival (PFS)(From date of the first cycle of neoadjuvant treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)Melanoma MetastaticNCT06586593Centre Hospitalier Universitaire de Besancon77
招募中
不适用
Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant ImmunotherapyNSCLCNCT06317558Cancer Institute and Hospital, Chinese Academy of Medical Sciences4,000
Unknown
不适用
Neoadjuvant Immunotherapy in Advanced NSCLCLung Cancer, Non-small CellNCT05137912Power Life Sciences Inc.10
招募中
不适用
Real-world Analysis on the Efficacy and Safety of Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinoma （neoHNSCC）Head and Neck Squamous Cell CarcinomaNCT06011993Second Affiliated Hospital, School of Medicine, Zhejiang University30
进行中（未招募）
不适用
a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC StudyThe Neoadjuvant Treatment for Resectable Esophageal Squamous Cell CarcinomaNCT06472635Zhejiang University95